Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Industry News

Shockwave Medical Announces FDA Clearance of the Company’s Lithoplasty® System, the First and Only Technology to Use Sound Waves to Treat Calcified Peripheral Artery Disease

September 16, 2016

News Industry News

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

July 11, 2016

News Industry News

Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease

October 12, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Lilly Provides Update on Evacetrapib Phase 3 Trial

July 27, 2015

News Industry News

Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet

July 23, 2015

News Industry News

Cardiovascular Systems Completes Coast Study Enrollment

July 14, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Industry News

Device to Sand Away Severe Calcium in Coronary Arteries Shows Long-Term Positive Results in a Difficult-to-Treat Patient Population

May 07, 2015

Advertisement

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

Shockwave Medical Announces FDA Clearance of the Company’s Lithoplasty® System, the First and Only Technology to Use Sound Waves to Treat Calcified Peripheral Artery Disease

FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor

Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Lilly Provides Update on Evacetrapib Phase 3 Trial

Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet

Cardiovascular Systems Completes Coast Study Enrollment

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Device to Sand Away Severe Calcium in Coronary Arteries Shows Long-Term Positive Results in a Difficult-to-Treat Patient Population

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content